In vitro susceptibility testing of imipenem-relebactam and tedizolid against 102 Mycobacterium abscessus isolates
Open Access
- 28 July 2023
- journal article
- research article
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 62 (4) , 106938
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Mycobacterium abscessus Smooth and Rough Morphotypes Form Antimicrobial-Tolerant Biofilm Phenotypes but Are Killed by Acetic AcidAntimicrobial Agents and Chemotherapy, 2018
- In vitro activity of tedizolid against the Mycobacterium abscessus complexDiagnostic Microbiology and Infectious Disease, 2018
- Imipenem–Relebactam and Meropenem–Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor CombinationsDrugs, 2017
- British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD)Thorax, 2017
- In Vitro Susceptibility Testing of Tedizolid against Nontuberculous MycobacteriaJournal of Clinical Microbiology, 2017
- US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis: executive summaryThorax, 2015
- Clonal Diversification and Changes in Lipid Traits and Colony Morphology in Mycobacterium abscessus Clinical IsolatesJournal of Clinical Microbiology, 2015
- Kraken: ultrafast metagenomic sequence classification using exact alignmentsGenome Biology, 2014
- Characterization of Rough and Smooth Morphotypes of Mycobacterium abscessus Isolates from Clinical SpecimensJournal of Clinical Microbiology, 2014
- Pulmonary Disposition of Tedizolid following Administration of Once-Daily Oral 200-Milligram Tedizolid Phosphate in Healthy Adult VolunteersAntimicrobial Agents and Chemotherapy, 2012